Merck Exercises its Option to License NGM’s NGM313 (MK-3655) for NASH and Type 2 Diabetics

 Merck Exercises its Option to License NGM’s NGM313 (MK-3655) for NASH and Type 2 Diabetics

Merck Exercises its Option to License NGM’s NGM313 (MK-3655) for NASH and Type 2 Diabetics

Shots:
  •  NGM to receive $20M as total deal value with anoption to participate in P-III trial of MK-3655 with equal cost and revenue sharing. Merck to get exclusive worldwide rights to develop and commercialize NGM’s NGM313 (currently MK-3655)
  • If the option is not exercised by NGM, it will receive milestones and royalties on sales
    of MK-3655. In 2015, Merck and NGM collaborated to develop therapies in multiple therapeutic areas
  • MK-3655 is an agonistic antibody involved in activation of β-Klotho/FGFR1c and binds to epitope of β-Klotho

 Click here to read full press release/ article | Ref: Merck & Co | Image: Biospace

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post